Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 313, Issue 7, 2015, Pages 677-686

  Torres, Antoni ^a,b,c,d   Sibila, Oriol ^e,f   Ferrer, Miquel ^a,b,c   Polverino, Eva ^a,b,c   Menendez, Rosario ^c,g   Mensa, Josep ^a,b   Gabarrús, Albert ^a,b,c   Sellarés, Jacobo ^a,b,c   Restrepo, Marcos I ^h,i,j   Anzueto, Antonio ^h,i   Niederman, Michael S ^k   Agustí, Carles ^a,b,c  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^j VERDICT   (United States)

^k WINTHROP UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHYLPREDNISOLONE; PLACEBO; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DELIRIUM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SUPERINFECTION; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; BLOOD; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; COMPARATIVE STUDY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PNEUMONIA; RESPIRATORY INSUFFICIENCY; SHOCK;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PNEUMONIA; RESPIRATORY INSUFFICIENCY; SHOCK; TREATMENT FAILURE;

EID: 84923125114     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.88     Document Type: Article

References (38)

1. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with communityacquired pneumonia: ameta-analysis. JAMA. 1996; 275(2):134-141.
2. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to theward and the ICU. Chest. 2008;133(3):610-617.
3. Menéndez R, Torres A, Zalacaín R, et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960-965.
4. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med. 2004;164(5):502-508.
5. Ramírez P, Ferrer M, Martí V, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011;39(10):2211-2217.
6. Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64(7):587-591.
7. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.
8. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005; 171(3):242-248.
9. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007;30(5):951-956.
10. Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96.
11. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-2030.
12. Salluh JI, Soares M, Coelho LM, et al. Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care. 2011;26(2):193-200.
13. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-982.
14. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: ameta-analysis. PLoS One. 2012;7(10):e47926.
15. Confalonieri M, Annane D, Antonaglia C, Santagiuliana M, Borriello EM, Meduri GU. Is prolonged low-dose glucocorticoid treatment beneficial in community-acquired pneumonia? Curr Infect Dis Rep. 2013;15(2):158-166.
16. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med. 1998; 158(4):1102-1108.
17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.
18. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008;63 (5):447-452.
19. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72.
20. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998;279(18):1452-1457.
21. Cillóniz C, Ewig S, Ferrer M, et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care. 2011;15(5):R209.
22. Alvarez-Lerma F, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care. 2004;10(5):369-374.
23. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137(3): 552-557.
24. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007;132(2):515-522.
25. Sibila O, Agustí C, Torres A, et al. Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response. Eur Respir J. 2007;30(6):1167-1172.
26. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107 (5):1342-1349.
27. Fernández-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol. 2003;10(5): 813-820.
28. Martínez R, Menéndez R, Reyes S, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011; 37(2):393-399.
29. Sibila O, Luna CM, Agustí C, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J. 2008;32(4):1037-1046.
30. Li Y, Cui X, Li X, et al. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med. 2008; 34(3):568-577.
31. Lisboa T, Blot S, Waterer GW, et al; Community-Acquired Pneumonia Intensive Care Units Study Investigators. Radiologic progression of pulmonary infiltrates predicts a worse prognosis in severe community-acquired pneumonia than bacteremia. Chest. 2009;135(1):165-172.
32. Otto GP, Sossdorf M, Claus RA, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15(4):R183.
33. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
34. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6): 954-963.
35. Remmelts HH, Meijvis SC, Heijligenberg R, et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect. 2012;65(1):25-31.
36. Nawab QU, Golden E, Confalonieri M, Umberger R, Meduri GU. Corticosteroid treatment in severe community-acquired pneumonia: duration of treatment affects control of systemic inflammation and clinical improvement. Intensive Care Med. 2011;37(9):1553-1554.
37. Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H; CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2012;55(8):1114-1121.
38. ClinicalTrials.gov website. ESCAPe trial: NCT01283009. https://clinicaltrials.gov/ct2/search/advanced. Accessibility verified January 28, 2015.